Gut microbiome alterations in patients with COVID-19-related coagulopathy

COVID-19 is characterized by a predominantly prothrombotic state, which underlies severe disease and poor outcomes. Imbalances of the gut microbiome have been linked with abnormal hemostatic processes. Understanding the relationship between the gut microbiome and abnormal coagulation parameters in C...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2023-06, Vol.102 (6), p.1589-1598
Main Authors: Chen, Youli, Li, Xin, Yu, Cheng, Wang, Erchuan, Luo, Chang, Jin, Yu, Zhang, Lei, Ma, Yanling, Jin, Yan, Yang, Ling, Sun, Binlian, Qiao, Jialu, Zhou, Xiang, Rasche, Leo, Einsele, Hermann, Song, Jun, Bai, Tao, Hou, Xiaohua
Format: Article
Language:English
Subjects:
Biomarkers
Blood Coagulation Disorders - etiology
Coronaviruses
COVID-19
COVID-19 - complications
Cross-Sectional Studies
Digestive system
Gastrointestinal Microbiome
Hematology
Humans
Medicine
Medicine & Public Health
Microbiota
Oncology
Original Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID-19 is characterized by a predominantly prothrombotic state, which underlies severe disease and poor outcomes. Imbalances of the gut microbiome have been linked with abnormal hemostatic processes. Understanding the relationship between the gut microbiome and abnormal coagulation parameters in COVID-19 could provide a novel framework for the diagnosis and management of COVID-related coagulopathies (CRC). This cross-sectional study used shotgun metagenomic sequencing to examine the gut microbiota of patients with CRC ( n = 66) and compared it to COVID control (CCs) ( n = 27) and non-COVID control (NCs) ( n = 22) groups. Three, 1, and 3 taxa were found enriched in CRCs, CCs, and NCs. Next, random forest models using 7 microbial biomarkers and differential clinical characteristics were constructed and achieved strong diagnostic potential in distinguishing CRC. Specifically, the most promising biomarker species for CRC were Streptococcus thermophilus , Enterococcus faecium , and Citrobacter portucalensis. Conversely, Enterobacteriaceae family and Fusicatenibacter genus are potentially protective against CRC in COVID patients. We further identified 4 species contributing to 20 MetaCyc pathways that were differentially abundant among groups, with S. thermophilus as the main coding species in CRCs. Our findings suggest that the alterations of gut microbiota compositional and functional profiles may influence the pathogenesis of CRC and that microbiota-based diagnosis and treatment could potentially benefit COVID patients in preventing and alleviating thrombosis-related clinical outcomes.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-023-05186-6